No Data
Wuhan Easy Diagnosis Biomedicine (002932.SZ): The first fundraising investment project has been completed, and the remaining funds will be used for Other fundraising investment projects.
On February 13, Gelonghui reported that Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that on February 13, 2025, the fourth Board of Directors held its eighteenth meeting and the fourth Supervisory Board held its fifteenth meeting, which reviewed and approved the proposal "Regarding the completion of the fundraising investment project for the initial public offering of Stocks and the use of the surplus funds for Other fundraising investment projects." The company agreed to finalize the fundraising investment project from the initial public offering of Stocks as a whole, and to use the surplus funds of 11.1108 million yuan (including financial returns, deposit interest, etc., with the final amount subject to the account on the day of fund transfer.
Wuhan Easy Diagnosis Biomedicine (002932.SZ): has cumulatively repurchased 5.61% of its shares.
Gelonghui reported on February 5 that Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that as of January 31, 2025, the company repurchased 13,034,741 shares through a dedicated repurchase securities account via centralized bidding (including parts used to maintain the company's value and shareholder rights), accounting for 5.61% of the company's total share capital; the highest Fill Price for the repurchased shares was 20.98 yuan/share, the lowest Fill Price was 15.33 yuan/share, and the total transaction amount was 0.248 billion yuan (excluding transaction taxes and fees).
Wuhan Easy Diagnosis Biomedicine (002932.SZ) has repurchased 5.05% of its shares, costing approximately 0.224 billion yuan.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) announced that, as of November 29, 2024, the company has cumulatively completed a total of...
Matilda Biotech: Report for the third quarter of 2024
wuhan easy diagnosis biomedicine (002932.SZ) released its performance for the first three quarters, with a net income of 80.9384 million yuan, a year-on-year decrease of 44.30%.
Wuhan Easy Diagnosis Biomedicine (002932.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Wuhan Easy Diagnosis Biomedicine (002932.SZ): net income for the first three quarters was 80.9384 million yuan, a year-on-year decrease of 44.30%.
Gelonghui on October 30th: wuhan easy diagnosis biomedicine (002932.SZ) announced the third quarter report for 2024, with the company's revenue of 0.226 billion yuan in the first three quarters, a year-on-year decrease of 63.95%; net income attributable to shareholders of the listed company was 80.9384 million yuan, a year-on-year decrease of 44.30%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -39.0766 million yuan; basic earnings per share was 0.35 yuan.